Gene · 5889
Papers3,668
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
921 to 940 of 3,668
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Chromosomal instability in adult-type diffuse gliomas. | Acta Neuropathol Commun | 2022 | 35978439 | PubTator, text mining | PubMed |
| Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial. | J Immunother Cancer | 2022 | 35977756 | PubTator, text mining | PubMed |
| GeneHome - a Novel Model to Deliver Care to Individuals with Genetic Predisposition to Cancer. | Cancer Control | 2022 | 35976772 | PubTator, text mining | PubMed |
| Advance trends in targeting homology-directed repair for accurate gene editing: An inclusive review of small molecules and modified CRISPR-Cas9 systems. | Bioimpacts | 2022 | 35975201 | PubTator, text mining | PubMed |
| Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients. | Genome Med | 2022 | 35971132 | PubTator, text mining | PubMed |
| RAD51 is a druggable target that sustains replication fork progression upon DNA replication stress. | PLoS One | 2022 | 35969531 | PubTator, text mining | PubMed |
| Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician's Perspective. | Cancer Manag Res | 2022 | 35967752 | PubTator, text mining | PubMed |
| The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma. | J Exp Clin Cancer Res | 2022 | 35964058 | PubTator, text mining | PubMed |
| Development and Validation of the PREMMplus Model for Multigene Hereditary Cancer Risk Assessment. | J Clin Oncol | 2022 | 35960913 | PubTator, text mining | PubMed |
| Association of GAB2 with Quality of Life and Negative Emotions in Patients with Gastric Cancer after Postoperative Comprehensive Care. | Evid Based Complement Alternat Med | 2022 | 35958936 | PubTator, text mining | PubMed |
| Hereditary Breast Cancer in the Brazilian State of Ceará (The CHANCE Cohort): Higher-Than-Expected Prevalence of Recurrent Germline Pathogenic Variants. | Front Oncol | 2022 | 35957908 | PubTator, text mining | PubMed |
| Correction of Fanconi Anemia Mutations Using Digital Genome Engineering. | Int J Mol Sci | 2022 | 35955545 | PubTator, text mining | PubMed |
| PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them. | Int J Mol Sci | 2022 | 35955544 | PubTator, text mining | PubMed |
| Detection of ESR1 Mutations in Primary Tumors and Plasma Cell-Free DNA in High-Grade Serous Ovarian Carcinoma Patients. | Cancers (Basel) | 2022 | 35954453 | PubTator, text mining | PubMed |
| RAD54B mutations enhance the sensitivity of ovarian cancer cells to poly(ADP-ribose) polymerase (PARP) inhibitors. | J Biol Chem | 2022 | 35952757 | PubTator, text mining | PubMed |
| Long-term survival of a BRCA2 mutation carrier following second ovarian cancer relapse using PARPi therapy: A case report. | Mol Clin Oncol | 2022 | 35949895 | PubTator, text mining | PubMed |
| Substitution mutational signatures in whole-genome-sequenced cancers in the UK population. | Science | 2022 | 35949260 | PubTator, text mining | PubMed |
| Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper. | Clin Cancer Res | 2022 | 35929986 | PubTator, text mining | PubMed |
| TP53-dependent toxicity of CRISPR/Cas9 cuts is differential across genomic loci and can confound genetic screening. | Nat Commun | 2022 | 35927263 | PubTator, text mining | PubMed |
| Genetic Testing and Its Clinical Application in Prostate Cancer Management: Consensus Statements from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology. | Front Oncol | 2022 | 35924163 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5889/papers?page=47